Skip to content

Clinical Observation and Mechanism Exploration of the Treatment of Multiple Myeloma with the Method of Tonifying Kidney Resolving Phlegm and Removing Stasis

A Mechanistic Study on the Treatment of Multiple Myeloma with Kidney-Tonifying Phlegm-Resolving and Stasis-Removing Therapy: Implications for Epigenetic Regulation of the Immunological Microenvironment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000449
Enrollment
Unknown
Registered
2025-03-04
Start date
2025-03-07
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

Integrated Traditional Chinese and Western Medicine Treatment Group:Basic supportive treatment plus primary disease treatment plus kidney tonifying phlegm resolving and blood stasis removing therapy
Western medicine control group:Basic supportive treatment plus primary disease treatment

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Western diagnostic criteria for multiple myeloma; 2. Meet the traditional Chinese medicine standards for multiple myeloma with kidney deficiency and phlegm stasis syndrome; 3. Age = 18 years old and = 80 years old gender not limited; 4. Willing to accept this treatment plan and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with allergic constitution or allergies to relevant MM treatment drugs; 2. Severe heart disease including myocardial infarction and heart failure grade 3 or above; 3. Patients with severe liver and kidney dysfunction (ALT>5 * ULN GRF<15ml/min); 4. Other systemic diseases with clinical significance such as osteoporosis bone metastases and lumbar tuberculosis; 5. Patients with two or more complications such as bone disease infection bleeding anemia etc; 6. Individuals with alcoholism drug abuse mental disorders and intellectual disabilities; 7. Pregnant or lactating women..

Design outcomes

Primary

MeasureTime frame
Number and proportion of T cell subpopulations;Number and proportion of NK cell subpopulations;NK cell activation and killing function;CD3+T cells;Immune checkpoint and T cell depletion molecules;

Secondary

MeasureTime frame
Whole blood cell count+C-reactive protein;Hematuria immunoglobulin M protein quantification free light chain ß 2-microglobulin;Whole body X-ray plain film or CT or MRI or PET CT;Western medicine efficacy evaluation;Safety indicators;Symptoms and signs;Quantitative integration of traditional Chinese medicine syndromes;Bone marrow examination;

Countries

China

Contacts

Public Contacthailin chen

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

chenhailinyyyy@163.com13651784266

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026